tiprankstipranks
Amylyx reports Q3 EPS (92c), consensus (97c)
The Fly

Amylyx reports Q3 EPS (92c), consensus (97c)

Reports Q3 revenue $345K, consensus $80K. "The third quarter has proven to be a transformative time for Amylyx and the ALS community, marked by the regulatory approval of our new oral therapy for the treatment of ALS in the United States and commercial availability of our first product in Canada," said Joshua Cohen and Justin Klee, Co-CEOs. "We are thrilled that RELYVRIO and ALBRIOZA are now available to people living with ALS in the U.S. and Canada, and we are encouraged by the early trajectory of enrollment in our Amylyx Care Team (ACT) Support Program as well as the rate of new prescriptions for this important new therapeutic option. We continue to work expeditiously during the early stages of our commercial launch to ensure every eligible person living with ALS will gain access as quickly and efficiently as possible."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AMLX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles